Ixekizumab Improves Outcomes of Ankylosing Spondylitis

NEW YORK (Reuters Health)—Ixekizumab improves signs and symptoms in patients with radiographic axial spondyloarthritis (ankylosing spondylitis), according to results from the COAST-W study. “Ankylosing spondylitis is a chronic and debilitating disease, and I have a large number of patients who have failed TNF inhibitors,” says Dr. Atul Deodhar from Oregon Health and Science University, Portland.... [Read More]

Source: The Rheumatologist - November 6, 2018 Category: Rheumatology Authors: Will Boggs, MD Tags: Biologics & Biosimilars Drug Updates Ankylosing spondylitis (AS) ixekizumab TNF inhibitor Source Type: research